NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.

NewAmsterdam Pharma Company N.V.

Needham analyst Serge Belanger maintained a Buy rating on NewAmsterdam Pharma Company today and set a price target of $48.00. Belanger covers the H...

Needham Remains a Buy on NewAmsterdam Pharma Company (NAMS)

BMO Capital analyst Conor MacKay maintained a Buy rating on NewAmsterdam Pharma Company yesterday and set a price target of $58.00. The company’s s...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	NAMS	$25.90	-3.32%	1.04M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	NAMS	$25.90	-3.3%	1.04M
3
4
5
6

NAMS

Get NewAmsterdam Pharma Company N.V. Data in Excel

Get NewAmsterdam Pharma Company N.V. Data in Excel